Table 2. Characteristics of the study population (ID=subject) including number or median, range and number of missings.
| Study 1 | Study 2 | Study 3 | Total | Missings | |
|---|---|---|---|---|---|
| Number of IDs, (male/female) | 17 (9/8) | 51 (33/18) | 22 (11/11) | 90 (53/37) | 0 |
| Age (years), median (min–max.) | 65 (40–82) | 57 (29–78) | 58 (30–71) | 60 (29–82) | 0 |
| Height (cm), median (min–max) | 168 (156–183) | 169 (143–198) | 170 (150–184) | 169 (143–198) | 3 |
| Weight (kg), median (min–max) | 68 (48–81) | 71 (47–125) | 72 (44–98) | 71 (44–125) | 3 |
| Body mass index (kg m−2), median (min–max) | 24.7 (17.0–30.7) | 25.8 (20.1–37.0) | 24.3 (15.9–33.9) | 24.9 (15.9–37.0) | 4 |
| Body surface area (m2), median (min–max) | 1.77 (1.51–2.01) | 1.82 (1.34–2.59) | 1.85 (1.44–2.16) | 1.82 (1.34–2.59) | 4 |
| Creatinine clearance (ml min−1), median (min–max) | 104 (71–480a) | 83 (47–180) | 108 (47–226) | 91 (41–480a) | 3 |
| Alkaline phosphatase (U l−1), median (min–max) | 190 (118–1026) | 156 (40–403) | 235 (96–1309) | 171 (40–1309) | 0 |
| Lactate dehydrogenase (U l−1), median (min–max) | 171 (117–926) | 542 (305–8041) | 187 (76–3243) | 426 (76–8041) | 0 |
| Study centre number (number of IDs) | 1 2 (8) (9) | 3 (51) | 4 (22) | 1 2 3 4 (8)(9)(51) (22) | 0 |
| Combination chemotherapy, number of IDs | 17 | 0 | 0 | 17 | 0 |
a
Spurious value in original data set, but without influence on population pharmacokinetic analysis.